Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target
© 2023. The Author(s)..
Safely expanding indications for cellular therapies has been challenging given a lack of highly cancer-specific surface markers. Here we explore the hypothesis that tumor cells express cancer-specific surface protein conformations that are invisible to standard target discovery pipelines evaluating gene or protein expression, and these conformations can be identified and immunotherapeutically targeted. We term this strategy integrating cross-linking mass spectrometry with glycoprotein surface capture 'structural surfaceomics'. As a proof of principle, we apply this technology to acute myeloid leukemia (AML), a hematologic malignancy with dismal outcomes and no known optimal immunotherapy target. We identify the activated conformation of integrin β2 as a structurally defined, widely expressed AML-specific target. We develop and characterize recombinant antibodies to this protein conformation and show that chimeric antigen receptor T cells eliminate AML cells and patient-derived xenografts without notable toxicity toward normal hematopoietic cells. Our findings validate an AML conformation-specific target antigen and demonstrate a tool kit for applying these strategies more broadly.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
---|---|
Enthalten in: |
Nature cancer - 4(2023), 11 vom: 30. Nov., Seite 1592-1609 |
Sprache: |
Englisch |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 27.11.2023 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s43018-023-00652-6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM363960244 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM363960244 | ||
003 | DE-627 | ||
005 | 20240210232830.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s43018-023-00652-6 |2 doi | |
028 | 5 | 2 | |a pubmed24n1287.xml |
035 | |a (DE-627)NLM363960244 | ||
035 | |a (NLM)37904046 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Mandal, Kamal |e verfasserin |4 aut | |
245 | 1 | 0 | |a Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.11.2023 | ||
500 | |a Date Revised 10.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a Safely expanding indications for cellular therapies has been challenging given a lack of highly cancer-specific surface markers. Here we explore the hypothesis that tumor cells express cancer-specific surface protein conformations that are invisible to standard target discovery pipelines evaluating gene or protein expression, and these conformations can be identified and immunotherapeutically targeted. We term this strategy integrating cross-linking mass spectrometry with glycoprotein surface capture 'structural surfaceomics'. As a proof of principle, we apply this technology to acute myeloid leukemia (AML), a hematologic malignancy with dismal outcomes and no known optimal immunotherapy target. We identify the activated conformation of integrin β2 as a structurally defined, widely expressed AML-specific target. We develop and characterize recombinant antibodies to this protein conformation and show that chimeric antigen receptor T cells eliminate AML cells and patient-derived xenografts without notable toxicity toward normal hematopoietic cells. Our findings validate an AML conformation-specific target antigen and demonstrate a tool kit for applying these strategies more broadly | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
650 | 7 | |a Integrins |2 NLM | |
700 | 1 | |a Wicaksono, Gianina |e verfasserin |4 aut | |
700 | 1 | |a Yu, Clinton |e verfasserin |4 aut | |
700 | 1 | |a Adams, Jarrett J |e verfasserin |4 aut | |
700 | 1 | |a Hoopmann, Michael R |e verfasserin |4 aut | |
700 | 1 | |a Temple, William C |e verfasserin |4 aut | |
700 | 1 | |a Izgutdina, Adila |e verfasserin |4 aut | |
700 | 1 | |a Escobar, Bonell Patiño |e verfasserin |4 aut | |
700 | 1 | |a Gorelik, Maryna |e verfasserin |4 aut | |
700 | 1 | |a Ihling, Christian H |e verfasserin |4 aut | |
700 | 1 | |a Nix, Matthew A |e verfasserin |4 aut | |
700 | 1 | |a Naik, Akul |e verfasserin |4 aut | |
700 | 1 | |a Xie, William H |e verfasserin |4 aut | |
700 | 1 | |a Hübner, Juwita |e verfasserin |4 aut | |
700 | 1 | |a Rollins, Lisa A |e verfasserin |4 aut | |
700 | 1 | |a Reid, Sandy M |e verfasserin |4 aut | |
700 | 1 | |a Ramos, Emilio |e verfasserin |4 aut | |
700 | 1 | |a Kasap, Corynn |e verfasserin |4 aut | |
700 | 1 | |a Steri, Veronica |e verfasserin |4 aut | |
700 | 1 | |a Serrano, Juan Antonio Camara |e verfasserin |4 aut | |
700 | 1 | |a Salangsang, Fernando |e verfasserin |4 aut | |
700 | 1 | |a Phojanakong, Paul |e verfasserin |4 aut | |
700 | 1 | |a McMillan, Melanie |e verfasserin |4 aut | |
700 | 1 | |a Gavallos, Victor |e verfasserin |4 aut | |
700 | 1 | |a Leavitt, Andrew D |e verfasserin |4 aut | |
700 | 1 | |a Logan, Aaron C |e verfasserin |4 aut | |
700 | 1 | |a Rooney, Cliona M |e verfasserin |4 aut | |
700 | 1 | |a Eyquem, Justin |e verfasserin |4 aut | |
700 | 1 | |a Sinz, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Huang, Benjamin J |e verfasserin |4 aut | |
700 | 1 | |a Stieglitz, Elliot |e verfasserin |4 aut | |
700 | 1 | |a Smith, Catherine C |e verfasserin |4 aut | |
700 | 1 | |a Moritz, Robert L |e verfasserin |4 aut | |
700 | 1 | |a Sidhu, Sachdev S |e verfasserin |4 aut | |
700 | 1 | |a Huang, Lan |e verfasserin |4 aut | |
700 | 1 | |a Wiita, Arun P |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature cancer |d 2020 |g 4(2023), 11 vom: 30. Nov., Seite 1592-1609 |w (DE-627)NLM307030067 |x 2662-1347 |7 nnns |
773 | 1 | 8 | |g volume:4 |g year:2023 |g number:11 |g day:30 |g month:11 |g pages:1592-1609 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s43018-023-00652-6 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 4 |j 2023 |e 11 |b 30 |c 11 |h 1592-1609 |